Navigation path

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece


   Infocentre

Published: 17 February 2016  
Related theme(s) and subtheme(s)
Health & life sciencesBiotechnology  |  Major diseases
Research policySeventh Framework Programme
Special CollectionsCancer
Success storiesHealth & life sciences
Countries involved in the project described in the article
France  |  Germany  |  Italy  |  Netherlands  |  Poland  |  Spain  |  United Kingdom
Add to PDF "basket"

Targeting lung cancer's Achilles heel

An EU-funded project has advanced lung cancer research by focusing on its weak spot - the epigenetic (or non-inherited) changes that differentiate cancer cells from healthy cells, making them prime targets for new therapies and earlier detection. The project results are already contributing to clinical trials and new screening tools.

Photo of a doctor looking at an xray
© Olesya Shelomova - Fotolia.com

Even when treated with a combination of chemotherapy, surgery and radiotherapy, survival rates for lung cancer, especially small cell lung cancer, are very low: on average only around 20% to 40% of patients diagnosed with Stage 2 lung cancers, at which point tumours are around 5cm in size, can expect to survive for five years or more with treatment.

Bringing together some of Europe’s leading specialists on genetics, epigenetics, pathology and oncology, the CURELUNG initiative has identified several epigenetic lung cancer biomarkers that could be potentially useful to target new therapies and early diagnosis.

The research is also contributing to the development of innovative tools to detect and characterise different types of lung cancer, and identify the most aggressive cancers in early-stage patients, as well as furthering clinical trials of new drugs.

“Not all cancers are the same, and not all patients will respond the same way to treatment. By identifying genetic alternations associated with specific cancer types we can create a list of biomarkers that can help determine the most effective, targeted treatment strategy for each individual patient while minimising the effect on healthy cells,” explains CURELUNG coordinator Manel Esteller, head of the Epigenetics and Cancer Biology Programme at Bellvitge Biomedical Research Institute (IDIBELL) in Spain.

Detecting cancer sooner

“One of the factors that makes lung cancer the most lethal type of cancer in the world is that it is usually diagnosed late, often after it has already metastasised and spread to other regions of the body. By identifying the biomarkers associated with lung cancer we can screen for them, allowing cancer to be detected and treated sooner, which should improve the effectiveness of therapies and increase survival rates,” Esteller says.

With that aim in mind, project partner MRC Holland, a biotech company, is building on work conducted in CURELUNG to develop screening tools for use in a clinical setting.

Equally important is determining the most effective course of treatment by identifying how drugs or combinations of drugs affect distinct forms of lung cancer brought on by different genetic alterations. In that regard, the biomarkers identified in CURELUNG are contributing to ongoing clinical trials in Germany run by pharmaceutical firms Novartis and AstraZeneca.

“The biomarkers we identified are being used by clinical researchers to determine if and how cancers with certain genetic alterations are affected by the drugs being tested, which should contribute to the development of new treatments for those cancer types,” the CURELUNG coordinator says.

With lung cancer accounting for 20% of all forms of cancer and causing the death of 1.6 million people worldwide each year – the most of any cancer – Esteller points out that if one drug is proven to be effective against 10% of lung cancers, and a second against another 10%, then the impact will only increase incrementally until a majority of lung cancers can be treated with targeted therapies.

Project details

  • Project acronym:CURELUNG
  • Participants:Spain (Coordinator), UK, France, Germany, Italy, Poland, Netherlands
  • Project Reference N° 258677
  • Total cost: € 3 849 117
  • EU contribution: € 2 965 749
  • Duration:January 2011 - June 2014

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Project information on CORDIS

Contacts
Unit A1 - External & internal communication,
Directorate-General for Research & Innovation,
European Commission
Tel : +32 2 298 45 40
  Top   Research Information Center
 
Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece